Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Audio By Carbonatix

FREMONT, Calif.--(BUSINESS WIRE)--Jan 28, 2026--

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 at the Cliff Lodge in Snowbird, UT.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X ( Twitter ).

View source version on businesswire.com:https://www.businesswire.com/news/home/20260128367499/en/

CONTACT: Investor Relations:

Caroline Corner

investors@personalis.com

415-202-5678

Media:

pr@personalis.com

KEYWORD: CALIFORNIA UTAH UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: ONCOLOGY HEALTH GENETICS HEALTH TECHNOLOGY MANAGED CARE BIOTECHNOLOGY

SOURCE: Personalis, Inc.

Copyright Business Wire 2026.

PUB: 01/28/2026 04:01 PM/DISC: 01/28/2026 04:02 PM

http://www.businesswire.com/news/home/20260128367499/en